BeOne Medicines, a global oncology company, recently received the approval from the National Medical Products Administration (NMPA) of China for the market launch of sonrotoclax, its foundational, next-generation B-cell lymphoma 2 (BCL2) inhibitor.

Based on the approval, the product will be used for adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

SIP Market Supervision Bureau and Drug Administration Center provided full support for the application for the approval, following up its progress and coordinating with related departments to help the company overcome challenges.

January 6, 2026